Что Дилакса помогает облегчить: Основные Области Применения

The core role of Дилакса is part of symptomatic management. The medication is considered relevant for easing symptom clusters across two main therapeutic areas: chronic inflammatory diseases and acute painful episodes.

It is commonly used to help with symptomatic relief in conditions such as Остеоартроз (OA), Ревматоидный артрит (RA), Анкилозирующий спондилит (AS), Ювенильный Ревматоидный Артрит (JRA), острая боль (acute pain) following procedures, and первичная дисменорея (menstrual cramps).

“This medicine is applied across domains where persistent боль (pain) and воспаление (inflammation) create noticeable interference with daily mobility.”

In these contexts, Дилакса generally supports symptoms that interfere with daily functioning, such as joint отек (swelling) and physical скованность (stiffness). It provides support that helps ease the overall symptom burden and may assist with maintaining functional stability, which contributes to easing the overall symptom load during periods of heightened symptoms.

---

Quick Fact: Supportive Management for Pain and Inflammation
Therapeutic Scope	Addresses chronic symptoms of arthritis and acute, short-term pain episodes.
Key Symptoms	Pain, joint stiffness, and inflammation/swelling.
Primary Benefit	Supports stability and comfort during periods of heightened symptoms.

Regulatory References

1. NIH DailyMed official prescribing information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults without specified contraindications.
• Children aged 2 years and older for the treatment of Juvenile Rheumatoid Arthritis.

Populations for whom use is not recommended (if applicable):

• Women in the first or second trimesters of pregnancy; use is contraindicated in the third trimester.
• Breastfeeding women; use is generally not recommended.
• Children younger than 2 years of age.

Populations for whom use is contraindicated:

• Patients with known sulfonamide allergy or hypersensitivity to celecoxib or other NSAIDs.
• Patients with a history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs.
• Patients with severe hepatic dysfunction (Child-Pugh Class C) or severe heart failure (NYHA Class II-IV).
• Patients with active peptic ulceration or active gastrointestinal bleeding.
• Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

---

Eligibility-Related Restrictions

Condition-specific eligibility rules:

• Severe renal dysfunction (GFR < 30 mL/min): Use is generally not recommended.
• Moderate hepatic impairment (Child-Pugh Class B): Use requires caution.
• Older Adults (65 years and older): Use requires special caution due to increased risk of serious adverse events.
• Cardiovascular Risk: Caution is advised for patients with established Ischaemic Heart Disease, Cerebrovascular Disease, or cardiovascular risk factors.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Celecoxib by establishing mandatory exclusions (contraindications) based on severe organ impairment, active GI pathology, and known hypersensitivity. Other populations, such as the elderly or those with moderate organ function impairment, are restricted to conditional use and require caution.

Interactions with other medicines and products

Official regulatory documents define specific restrictions and requirements for the co-administration of Dilaxa (Celecoxib) with other substances.

Contraindicated Combinations

Co-administration with other non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is strictly contraindicated. Its use is also prohibited for treating pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Pharmacokinetic and Exposure-Altering Interactions

The metabolism of Celecoxib primarily involves the CYP2C9 enzyme. Co-administration with strong CYP2C9 inhibitors, such as Fluconazole, leads to a two-fold increase in Celecoxib plasma concentrations (AUC).

Separately, co-administration with Lithium and Digoxin can increase the serum concentrations of these drugs by reducing their renal clearance. Aluminum- and magnesium-containing Antacids may decrease the peak plasma concentration of Celecoxib by approximately 37%.

Pharmacodynamic and Bleeding Risk

Concomitant use with oral anticoagulants (e.g., Warfarin) is associated with an increased risk of serious bleeding events, requiring mandatory monitoring. This heightened bleeding risk also extends to co-administration with SSRIs and SNRIs. Furthermore, Celecoxib may diminish the antihypertensive effect of ACE inhibitors, ARBs, and diuretics, an effect documented in regulatory labeling.

Population-Specific Notes

Individuals classified as poor CYP2C9 metabolizers may experience significantly higher systemic exposure to Celecoxib. Use in patients with severe hepatic impairment is not recommended.

How Дилакса Works

The mechanism of action for Дилакса (Целекоксиб) is based on targeted molecular interference within specific biological signaling pathways. The core mechanism is defined by the suppression of specific chemical mediator production.

---

Targeted Inhibition of the COX-2 Enzyme

Дилакса operates by selectively inhibiting the enzyme Циклооксигеназа-2 ( COX-2). This enzyme is primarily induced during tissue stress, where it acts as a key component in a specific chemical pathway. The targeted molecular action prevents the COX-2 enzyme from completing its catalytic function, reducing the rate of prostanoid synthesis.

---

Disruption of Prostaglandin Biosynthesis

The blockage of COX-2 immediately disrupts the Арахидоновая кислота cascade, causing a localized reduction in the synthesis of specific molecular messengers, chiefly Простагландин Е2 ( PGE2). This suppression of molecular messengers constitutes the physiological step that regulates the magnitude of the inflammatory cascade and associated fluid dynamics.

---

Modulation of Nociceptor Sensitization

By lowering the available concentration of PGE2, the drug's mechanism leads to a stabilization of the nervous system's responsiveness. The reduction in PGE2 prevents the sensitization of peripheral pain fibers (nociceptors) and spinal neurons, resulting in a regulated threshold for signal initiation and transmission.

How to Use Дилакса: Official Administration Guidelines

The principles for using Дилакса (celecoxib) emphasize the lowest effective dose for the shortest duration consistent with treatment goals. The medicine is administered orally in hard capsule form, with strengths including 50 mg, 100 mg, 200 mg, and 400 mg.

---

Standard Dosing and Frequency

Usage patterns vary based on the required symptomatic relief, typically falling between 200 mg and 400 mg per day, with the maximum recommended dose for all primary indications being 400 mg daily.

Indication	Dosing Regimen	Maximum Daily Dose
Osteoarthritis (OA)	200 mg once daily (OD) or 100 mg twice daily (BID).	400 mg
Acute Pain / Primary Dysmenorrhea	Initial 400 mg dose, followed by 200 mg BID as needed.	400 mg
Ankylosing Spondylitis (AS)	200 mg OD or 100 mg BID; may increase to 400 mg after 6 weeks if needed.	400 mg

---

Administration Context and Adjustments

Дилакса can be taken with or without food. If difficulty swallowing the capsule occurs, the contents may be sprinkled onto a level teaspoon of cool or room temperature applesauce, rice gruel, yogurt, or mashed banana and must be ingested immediately.

Specific dosage reductions are utilized for certain populations. For example, individuals with moderate hepatic impairment (Child-Pugh Class B) require a 50% reduction in the standard daily dose. Furthermore, those identified as CYP2C9 poor metabolizers may also require a reduced dosage, sometimes to half the lowest recommended dose. Treatment for chronic conditions involves periodic re-evaluation to determine continued necessity and minimize overall duration of use.

Overview of Studies on Dilaxa (Celecoxib)

Research Exploring Chronic Inflammation Symptom Patterns

Numerous Randomized Controlled Trials (RCTs), considered a type of clinical study, have been used in research exploring how symptoms change over time in adults with chronic inflammatory conditions. These studies have also been summarized in systematic reviews and meta-analyses. The focus was on studies focusing on episodes where symptoms become more noticeable.

Research in Osteoarthritis (OA) and Rheumatoid Arthritis (RA)

Research work was applied in studies examining patient-reported experiences in conditions characterized by functional limitations and pain associated with OA and RA. Studies monitored outcomes related to physical discomfort, such as pain intensity scales, and outcomes reflecting daily functioning (e.g., functional scales). Studies report how symptoms evolved in the observed populations in pain and stiffness assessments. Most data for RA were derived from settings where Celecoxib was used in addition to other, long-term therapies.

Research in Ankylosing Spondylitis (AS)

Research related to AS also consisted of RCTs which examined patients with active AS. Studies monitored outcomes linked to inflammatory or irritative states, such as back pain and morning stiffness. Studies monitored symptom patterns in the observed populations in the short term regarding disease activity indices and functional measures. Follow-up durations were limited in the core registration trials.

Evidence in Research Scenarios Exploring Acute Symptom Patterns

This class of research was applied in studies examining short-term or episodic symptom patterns, such as acute pain following surgical procedures and menstrual discomfort. These studies focused on episodes where symptoms become more noticeable.

Application in Acute Pain and Post-Operative Scenarios

Research was conducted using short-term RCTs in conditions associated with acute or disruptive episodes of pain. Studies monitored outcomes related to physical discomfort, such as pain intensity on visual analog scales, and the need for supplemental pain medication (rescue analgesia).

Research in Special Populations

Research in Juvenile Rheumatoid Arthritis (JRA)

Research was conducted in a population of pediatric patients (starting at 2 years of age) with polyarticular JRA. These RCTs examined changes measured during the study period using specific JRA improvement criteria. Sample sizes were modest compared to adult trials, and results apply only to the populations studied.

What Is Still Uncertain and Gaps in the Evidence Base

Long-term effects are not fully established regarding the long-term impact on the structure of joint diseases. Data for certain groups remain insufficient, such as patients with severe concomitant diseases. Comparative evidence is lacking for a direct long-term comparison with all existing treatment methods. Research focusing on episodes where symptoms become more noticeable contributes to the broader evidence landscape, but findings describe group patterns, not personal outcomes.

Key Studies & References

1. Celecoxib for the Treatment of Ankylosing Spondylitis - Symbiosis Online Publishing (Review of multiple RCTs for AS, BASDAI/BASFI indices, and long-term data)

Common questions about Дилакса (FAQ)

---

Q: What does the drug class of Дилакса mean in simple terms?

According to official product information, Дилакса is classified as a selective COX-2 inhibitor. Official product information describes its action as specifically targeting and blocking the Cyclooxygenase-2 (COX-2) enzyme. This targeted action helps to reduce the production of chemical mediators, such as prostaglandins, which are responsible for transmitting pain and promoting inflammation.

---

Q: Can Дилакса be taken at the same time as common cold medicines?

Official regulatory documents state that this medicine should not be combined with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which are often found in common cold or flu remedies. Official labeling indicates that combining it with certain cold medicine ingredients may lead to changes in their blood levels.

---

Q: What do the official prescribing documents say about the success rate of Дилакса?

Studies summarized in the regulatory documents indicate that the medicine provides effective symptomatic treatment for its approved uses, such as Osteoarthritis and Rheumatoid Arthritis. Studies indicate that the symptomatic relief offered is similar to that of other non-selective NSAIDs used in clinical trials. These findings describe group patterns, not personal outcomes.

---

Q: Is Дилакса addictive or habit-forming?

According to the official product labeling, this medicine is not classified as a controlled substance. The regulatory documents do not contain any specific warnings or statements regarding the risk of addiction or habit-forming effects.

---

Q: How long do the effects of Дилакса usually last after the full course of treatment is finished?

Official information on the drug's properties states that the half-life of the active ingredient is approximately 11 hours. This indicates that the medicine is processed and cleared from the body. Following the completion of a full course, the active substance is typically cleared from the system within a few days.

---

Q: Does Дилакса interact with common herbal supplements like St. John's Wort?

Regulatory drug interaction information reports that the herbal supplement St. John's Wort may reduce the blood concentration of the active ingredient, celecoxib. This interaction could potentially lead to reduced effectiveness of the medicine.

---

Q: Does Дилакса help with sleep, even though it's for another main indication?

The official product information does not indicate that this medicine helps with sleep. Instead, Insomnia (difficulty sleeping) has been reported in clinical trials as a possible adverse reaction to the medicine.

---

Q: Does using Дилакса affect the results of any routine lab tests?

According to regulatory documentation, periodic monitoring of certain laboratory parameters is recommended, particularly during long-term use. This monitoring can include checks of a complete blood count (CBC) and tests assessing kidney and liver function.

How to Store and Dispose of Dilaxa (Celecoxib)

Official regulatory guidelines define strict conditions for the storage and disposal of this medicine, focusing on temperature control and safety.

Required Storage Conditions

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature, typically 25 C (77 F), permitting excursions between 15 C and 30 C.
Environmental	Keep the product in its original container, tightly closed, in a cool, dry place. The medicine must not be refrigerated or frozen.
Child Safety	Keep out of reach of children and store the product in a secure location.

Official Disposal Rules

Expired or unused Dilaxa must be disposed of in accordance with local regulations for pharmaceutical waste. The medicine must not be flushed down the toilet or discarded with household trash to prevent environmental release. Unused capsules should be returned to a local pharmacy for proper destruction.